Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement Rallybio Corporation and Avenzo Therapeutics, Inc. a clinical-stage biotechnology company developing next-generation oncology therapies, announced that they have entered into a definitive…
Secretome Therapeutics Announces $30 Million Series A Financing From RA Capital Management to Advance STM-01 for Duchenne-Associated Cardiomyopathy Secretome Therapeutics, a clinical-stage biotechnology company developing novel therapies derived from neonatal cardiac progenitor cells (nCPC), announced the closing of a $30…
Turn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36 Associated Inflammatory Model Turn Therapeutics Inc. a clinical-stage biotechnology company focused on developing localized therapies for inflammatory and infectious skin diseases, announced the publication of…
Sustained Therapeutics Presents Positive Phase 2 Data for ST-01 in Podium Presentation at the American Urological Association 2026 Annual Meeting Sustained Therapeutics, Inc. a clinical-stage urologic therapeutics company advancing differentiated therapies for underserved conditions, today presented additional data from its…
Turn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as Executive Clinical and Regulatory Lead Turn Therapeutics Inc. a clinical-stage biotechnology company developing targeted, localized therapies for inflammatory skin diseases, announced the appointment of Stephen M. Hahn,…
Scribe Therapeutics Reports Preclinical Data at ASGCT 2026 Demonstrating Enhanced Potency and Specificity of Engineered CRISPR Technologies for Epigenetic Silencing and Gene Editing Scribe Therapeutics, Inc. a biotechnology company engineering purpose-built CRISPR technologies to reshape the treatment of disease by…
Dyno Therapeutics Announces Expanded Frontiers Network and Second Annual Genetic Agency Technology Conference (GATC) Dyno Therapeutics, Inc., a genetic technologies company applying artificial intelligence (AI) to solve the grand challenge of in vivo gene delivery, announced significant updates to two mission-driven initiatives:…
Cellares and ProTgen Partner to Automate Manufacturing for ProT-096, a Novel Progenitor T Cell Therapy Designed to Restore Immune Competence Cellares, the first Integrated Development and Manufacturing Organization and ProTgen, a biotechnology company pioneering targeted Notch activators to reactivate the…
Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock Viridian Therapeutics, Inc. a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for autoimmune and…
UCB to Acquire Candid Therapeutics, Building Upon Its Existing Immunology Pipeline With Novel T-cell Engagers UCB, a global biopharmaceutical company, announced signing of a definitive agreement under which it would acquire Candid Therapeutics (Candid), a privately held clinical-stage biotechnology company…
Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the First and Only Approved Medicine for FSGS Travere Therapeutics, Inc., announced that the U.S. Food and Drug Administration (FDA) has approved FILSPARI® (sparsentan) to reduce proteinuria in adult and pediatric patients…
Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALS Coya Therapeutics, Inc. a clinical-stage biotechnology company developing biologics intended to enhance Treg function, announces the…